MedTrace Logo

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38831

Last updated 2017-04-05

No results posted yet for this study

Summary

To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

DRUG

VKA (Vitamin K antagonist)

As prescribed by treating physicians

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-12
Primary Completion
2016-03-01
Completion
2016-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690155 on ClinicalTrials.gov